Fundamental Analysis of Mereo BioPharma Group PLC - Growth / Value Index
MREO - Valuation Highlights
Valuation Analysis
Tsr Value Index - Poor Score of 21.88
Price to Book Ratio of 33.35 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -61.14 | -71616.53 | -634280.52 % | |
| Price to Book | 39.70 | 41756.59 | 669094 % | 52.31 |
| Price to Sales | 221.96 | 211025 | 82277.57 % | |
| Enterprise Value to EBITDA Multiple | -10.83 | -74260.99 | -915196.51 % |
MREO - Profitability Highlights
Profitability Analysis
Piotroski F Score - Stable Value of 5.0
Steady Growth in EPS for last four quarters
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -64.93 | -58.31 | -5.49 % | -20.89 |
| Return On Asset | -47.28 | -44.31 | -14.13 % | -16.00 |
| Net Profit Margin | -363.04 | -294.66 | 87.01 % | 0 |
| Operating Profit Margin | -387.31 | -284.16 | 90.17 % | 0 |
| EBITDA Margin | -378.17 | -284.16 | 89.82 % | 0 |
Highlights
| Market Cap | 448870 K |
| Enterprise Value | 396495 K |
| Price/Book TTM | 39.70 |
| Outstanding Share | 140272 K |
| Float/ Outstanding Share | 313.68% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 5.00 |
| Altman Z Score | 7.71 |
| Sloan Ratio | -0.125 |
| Peter Lynch Fair Value | 0 |
MREO - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 9684.61 K | 563.57 % | 100.00 % |
| Gross Profit | 5769.14 K | 693.38 % | 100.00 % |
| EBITDA | -36624.36 K | 32.44 % | 79.86 % |
| Net Profit | -35159.21 K | 13.83 % | 48.03 % |
| EPS | -0.052 | 99.98 % | NA |
MREO - Stability Highlights
Stability Analysis
Altman Z Score of 6.44 suggests good Stability
Paid More Than 50% of Debt, Heading towards debt free
Cash ratio of 6.05
Company is unable to generate enough free cash to support the business.
Interest Coverage of -10.06
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.100 | -46.52 % | 0.0155 |
| Cash Ratio | 6.05 | 165.16 % | |
| Quick Ratio | 6.59 | 150.95 % | 4.75 |
| Shareholders Equity | 76.00 | 8.19 % | |
| Debt to EBITDA | -0.178 | 35.34 % |
Historical Valuation Ratios of Mereo BioPharma Group PLC
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Mereo BioPharma Group PLC
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Mereo BioPharma Group PLC
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Mereo BioPharma Group PLC
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)